Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
47 hedge funds and large institutions have $97.4M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
18% more funds holding
Funds holding: 40 → 47 (+7)
10% more capital invested
Capital invested by funds: $88.2M → $97.4M (+$9.22M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$6.26M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$3.95M |
| 3 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$3.37M |
| 4 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$2.56M |
| 5 |
IAM
Ion Asset Management
Herzliya,
Israel
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NEPWA
New England Private Wealth Advisors
Wellesley,
Massachusetts
|
-$848K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$104K |
| 3 |
Bank of New York Mellon
New York
|
-$78.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$65.7K |
| 5 |
Goldman Sachs
New York
|
-$44.6K |
ELOX Hedge Fund Activity: Q2 2019 in Review
47 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q2 2019, worth a combined $97.4M — up 10% from $88.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ELOX positions and 0 closed out — a net gain of 9 holders — while 20 added to existing stakes and 10 trimmed.
The largest buyer was Clal Insurance, opening a new position worth an estimated $6.26M. The largest seller was New England Private Wealth Advisors, cutting an estimated $848K.
- 47 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q2 2019, up from 40 in Q1 2019.
- Funds reported $97.4M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q2 2019, up 10% quarter-over-quarter.
- 9 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +9 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Clal Insurance, an estimated $6.26M added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was New England Private Wealth Advisors, an estimated $848K sold.
Based on aggregated 13F filings for Q2 2019.